In the original article, the author's name Filippo Gurgoglione was incorrectly given as Filippo Gurguglione. The original article has been corrected.
-
2022 (v1)PublicationUploaded on: February 14, 2024
-
2023 (v1)Publication
BACKGROUND: Microvascular obstruction (MVO) is a frequent occurrence after primary percutaneous coronary intervention (pPCI), and is associated with adverse left ventricular remodeling and worse clinical outcome. Distal embolization of thrombotic material is one of the most important underlying mechanisms. The aim of this study was to...
Uploaded on: July 3, 2024 -
2020 (v1)Publication
Background: Ticagrelor is a reversibly binding, direct-acting, oral, P2Y12 antagonist used for the prevention of atherothrombotic events in patients with coronary artery disease (CAD). Ticagrelor blocks adenosine reuptake through the inhibition of equilibrative nucleoside transporter 1 (ENT-1) on erythrocytes and platelets, thereby facilitating...
Uploaded on: April 14, 2023 -
2022 (v1)Publication
Background: While the importance of invasive physiological assessment (IPA) to choose coronary lesions to be treated is ascertained, its role after PCI is less established. We evaluated feasibility and efficacy of Physiology-guided PCI in the everyday practice in a retrospective registry performed in a single high-volume and...
Uploaded on: February 7, 2024 -
2019 (v1)Publication
Importance: At one end of the coronary artery disease (CAD) spectrum, there are patients with multiple recurrent acute coronary syndromes (rACS), and at the other end there are those with long-standing clinical stability. Predicting the natural history of these patients is challenging because unstable plaques often heal without resulting in...
Uploaded on: April 14, 2023